News Related to First-in-Class Therapy

Related coverage linked through entity extraction aliases.

Merck/Gilead Discontinue Lung Cancer Trial as Pfizer, Roivant Report Pipeline Updates

Jun 09, 2026

Merck and Gilead discontinued a Phase 3 lung cancer trial due to lack of statistical significance, while Pfizer initiated a new Phase 1 trial and Roivant Sciences completed enrollment in its Phase 2 PHocus trial for pulmonary hypertension.

Immunic Presents New Phase 2 CALLIPER Data, Secures $400M for Vidofludimus Calcium

May 28, 2026

Immunic presented new Phase 2 CALLIPER data at CMSC 2026 showing vidofludimus calcium's favorable effects in progressive MS, including a novel unified disability endpoint. The company also secured $400M in private placement to fund Phase 3 ENSURE studies and commercial preparations.